Combination photodynamic therapy and intravitreal ranibizumab in neovascular amd in a north indian population: A pilot study

Retina

Volumn 28, Issue 8, 2008, Pages 1132-1137

  Kumar, Atul ^a   Gopalakrishnan, Kiran ^a   Sinha, Subijoy ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB; VERTEPORFIN; MONOCLONAL ANTIBODY; PHOTOSENSITIZING AGENT; PORPHYRIN;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTRAST SENSITIVITY; EYE EXAMINATION; FEMALE; FOLLOW UP; HUMAN; INDIA; INTERVENTION STUDY; MALE; OUTCOME ASSESSMENT; PHOTODYNAMIC THERAPY; PILOT STUDY; PROSPECTIVE STUDY; RETINA MACULA AGE RELATED DEGENERATION; RETREATMENT; SUBRETINAL NEOVASCULARIZATION; THERAPY EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VISION; VISUAL ACUITY; ASIAN; DRUG COMBINATION; DRUG EFFECT; ETHNOLOGY; INJECTION; MIDDLE AGED; PATHOPHYSIOLOGY; PHOTOCHEMOTHERAPY; RETINA MACULA DEGENERATION; STATISTICS; VITREOUS BODY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ASIAN CONTINENTAL ANCESTRY GROUP; CHOROIDAL NEOVASCULARIZATION; CONTRAST SENSITIVITY; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INDIA; INJECTIONS; MACULAR DEGENERATION; MALE; MIDDLE AGED; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PILOT PROJECTS; PORPHYRINS; PROSPECTIVE STUDIES; RETREATMENT; TREATMENT OUTCOME; VISUAL ACUITY; VITREOUS BODY;

EID: 58149231433     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e318170d76d     Document Type: Article

References (19)

1. Vingerling JR, Diclemans IJ, Hofmann A, et al. The prevalence of age related maculopathy in Rotterdam study. Ophthalmology 1995;102:205-210.
2. Nirmalin PK, Katz J, Robin AL, et al. Prevalence of vitreo-retinal disorders in a rural population of South India. The Aravind Comprehensive Eye Study. Arch Ophthalmol 2004; 122:581-586.
3. Klein R, Klein BE, Linton KL. Prevalence of age related maculopathy. The Beaver Dam Eye Study. Ophthalmology 1992;99:933-943.
4. Hussain N, Das T, Khanna R, et al. Verteporfin therapy for neovascular age related macular degeneration in Indian eyes. Jpn J Ophthalmol 2006;50:524-528.
5. Miller JW, Schmidt-Erfurth U, Sickenberg M, et al. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of a single treatment in a phase 1 and 2 study. Arch Ophthalmol 1999;117:1161-1173.
6. Verteporfin in Photodynamic Therapy Study Group. Verte-porfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization - Verteporfin in Photo-dynamic Therapy report 2. Am J Ophthalmol 2001;131:541-560.
7. Heier JS, Boyer DS, Gulla TA, et al. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study. Arch Ophthalmol 2006;124:1932-1942.
8. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age related macular degeneration. ANCHOR Study Group. N Engl J Med 2006;355: 1432-1444.
9. Ferrara N, Damico L, Shams N, et al. Development of ranibi-zumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 2006;26:859-870.
10. Boyer DS, Antoszyk AN, Awh CC, et al. Subgroup analysis of the MARINA Study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 2007;114:246-252.
11. Kaiser PK. Verteporfin photodynamic therapy and anti-an-giogenic drugs: potential for combination therapy in age- related macular degeneration. Curr Med Res Opin 2007;23: 477-487.
12. Rosenfeld PJ, Rich RM, Lalwani GA. Ranibizumab: phase III clinical trial results. Ophthalmol Clin North Am 2006;19:361-372.
13. Blick SK, Keating GM, Waqstaff AJ. Ranibizumab. Drugs 2007;67:1199-1206.
14. Regillo CD, Brown DM, Abraham P, et al. Randomized, double-masked, sham controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study Year 1. Am J Ophthalmol 2008;145:239-248.
15. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007; 143:566-583.
16. Spaide R. Ranibizumab according to need: a treatment for age-related macular degeneration. Am J Ophthalmol 2007; 143:679-680.
17. Kumar A, Sinha S, Kumar V. Visual acuity and contrast sensitivity outcomes in Indian eyes undergoing photody-namic therapy with intravitreal injection of triamcinolone acetonide in age related macular degeneration. Indian J Ophthalmol 2007;55:207-211.
18. Hussein N, Das T, Rawal H, et al. Combination therapy of intravitreal triamcinolone and photodynamic therapy with verteporfin for subfoveal choroidal neovascularisation. Indian J Ophthalmol 2006;54:247-250.
19. Dhalla MS, Shah GK, Binder KJ, et al. Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for choroidal neovascularisation in age related macular degeneration. Retina 2006;26:988-993.